JP2015505818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505818A5 JP2015505818A5 JP2014541396A JP2014541396A JP2015505818A5 JP 2015505818 A5 JP2015505818 A5 JP 2015505818A5 JP 2014541396 A JP2014541396 A JP 2014541396A JP 2014541396 A JP2014541396 A JP 2014541396A JP 2015505818 A5 JP2015505818 A5 JP 2015505818A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- fgfr1
- therapeutic agent
- agent according
- ecd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161559259P | 2011-11-14 | 2011-11-14 | |
| US61/559,259 | 2011-11-14 | ||
| US201261616761P | 2012-03-28 | 2012-03-28 | |
| US61/616,761 | 2012-03-28 | ||
| PCT/US2012/064772 WO2013074492A1 (en) | 2011-11-14 | 2012-11-13 | Methods of treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091502A Division JP6578318B2 (ja) | 2011-11-14 | 2017-05-02 | 癌を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505818A JP2015505818A (ja) | 2015-02-26 |
| JP2015505818A5 true JP2015505818A5 (https=) | 2017-01-05 |
Family
ID=48430074
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541396A Pending JP2015505818A (ja) | 2011-11-14 | 2012-11-13 | 癌を治療する方法 |
| JP2017091502A Active JP6578318B2 (ja) | 2011-11-14 | 2017-05-02 | 癌を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091502A Active JP6578318B2 (ja) | 2011-11-14 | 2017-05-02 | 癌を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10016484B2 (https=) |
| EP (1) | EP2780033B1 (https=) |
| JP (2) | JP2015505818A (https=) |
| CN (2) | CN107823630A (https=) |
| AU (1) | AU2012318247B2 (https=) |
| CA (1) | CA2855818A1 (https=) |
| HK (2) | HK1201462A1 (https=) |
| TW (1) | TW201326201A (https=) |
| WO (1) | WO2013074492A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| EP2318529B1 (en) | 2008-08-04 | 2017-10-18 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
| LT2498799T (lt) | 2009-11-13 | 2016-11-10 | Five Prime Therapeutics, Inc. | Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| CN107823630A (zh) | 2011-11-14 | 2018-03-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
| TW201427681A (zh) | 2013-01-07 | 2014-07-16 | Superlab Far East Ltd | 用空間構象改變的重組干擾素治療腫瘤的方法 |
| US20160067307A1 (en) * | 2013-05-01 | 2016-03-10 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
| US10877024B2 (en) * | 2015-05-12 | 2020-12-29 | Superlab Far East Limited | Methods of determining interferon having direct inhibitory effects on tumors and uses thereof |
| MX2018006181A (es) * | 2015-11-23 | 2018-09-24 | Five Prime Therapeutics Inc | Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer. |
| CN107794293A (zh) * | 2016-08-31 | 2018-03-13 | 安诺优达基因科技(北京)有限公司 | 一种基因捕获试剂盒 |
| CN109609640A (zh) * | 2019-01-14 | 2019-04-12 | 中国科学院上海高等研究院 | Etv4的用途 |
| JP7510998B2 (ja) * | 2019-08-05 | 2024-07-04 | 北京基石生命科技有限公司 | 肺がん固形腫瘍の初代細胞と肺がん胸水の初代腫瘍細胞の培養方法およびキット |
| CN111735950B (zh) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Fgf18和ca125联合用作早期卵巢癌生物标志物以及试剂盒 |
| CN111912987B (zh) * | 2020-08-25 | 2023-07-21 | 北京信诺卫康科技有限公司 | Fgf18和he4联合用作早期卵巢癌生物标志物以及试剂盒 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486462A (en) | 1984-11-23 | 1996-01-23 | The Regents Of The University Of California | Differentiative expression modules |
| US5288855A (en) | 1989-01-23 | 1994-02-22 | Farmitalia Carlo Erba | Extracellular form of the human fibroblast growth factor receptor |
| GB9001466D0 (en) | 1990-01-23 | 1990-03-21 | Erba Carlo Spa | Extracellular form of the human fibroblast growth factor receptor |
| HU215581B (hu) | 1989-07-06 | 1999-01-28 | Regents Of The University Of California | Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására |
| US5750371A (en) | 1990-04-27 | 1998-05-12 | Takeda Chemical Industries Ltd | Water-soluble mutein of FGF receptor, DNA and production thereof |
| EP0538404B1 (en) | 1990-07-06 | 2003-06-18 | Rhone-Poulenc Rorer International (Holdings) Inc. | Fibroblast growth factor receptors |
| US5863888A (en) | 1990-07-06 | 1999-01-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Human Bek Fibroblast growth factor receptor |
| US5229501A (en) * | 1991-01-11 | 1993-07-20 | Chiron Corporation | Expression and use of human fibroblast growth factor receptor |
| IL100219A0 (en) | 1991-12-02 | 1992-09-06 | Yeda Res & Dev | Variable region within fibroblast growth factor receptors that confers ligand specificity |
| US5474914A (en) | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
| US6517872B1 (en) | 1995-06-12 | 2003-02-11 | Yeda Research And Development Co., Ltd. | FGFR3 as a marker for mesenchymal skeletal progenitor cells |
| WO1997048813A2 (en) | 1996-06-18 | 1997-12-24 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Fibroblast growth factor receptor activating gene 1 (frag1). fgfr2-frag1 fusions |
| DE19802377A1 (de) | 1998-01-22 | 1999-08-19 | Max Planck Gesellschaft | Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs |
| US6656728B1 (en) * | 1999-02-08 | 2003-12-02 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
| US7135311B1 (en) | 1999-05-05 | 2006-11-14 | Institut Curie | Means for detecting and treating pathologies linked to FGFR3 |
| BRPI0209933B8 (pt) | 2001-05-24 | 2021-05-25 | Zymogenetics Inc | proteína de fusão, e, molécula de ácido nucleico |
| WO2003038054A2 (en) | 2001-10-31 | 2003-05-08 | New York University | Structure-based design and synthesis of fgf inhibitors and fgf modulator compounds |
| EP1543106B1 (en) | 2002-07-15 | 2007-04-11 | Immunex Corporation | Methods and media for controlling sialylation of proteins produced by mammalian cells |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| IL156495A0 (en) | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| EP1697420A2 (en) | 2003-12-19 | 2006-09-06 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| CA2565974A1 (en) | 2004-05-14 | 2005-12-01 | Receptor Biologix, Inc. | Cell surface receptor isoforms and methods of identifying and using the same |
| WO2005115363A2 (en) | 2004-05-25 | 2005-12-08 | Yale University | Method for treating skeletal disorders resulting from fgfr malfunction |
| CA2589895A1 (en) | 2005-01-27 | 2006-08-03 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
| US20060234347A1 (en) | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| WO2007059574A1 (en) | 2005-11-23 | 2007-05-31 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| ES2582652T3 (es) | 2006-02-10 | 2016-09-14 | Genentech, Inc. | Anticuerpos anti-FGF19 y métodos de uso de los mismos |
| JP2009536834A (ja) | 2006-05-12 | 2009-10-22 | ジェネンテック・インコーポレーテッド | 癌の診断及び治療のための方法及び組成物 |
| AR063975A1 (es) | 2006-11-28 | 2009-03-04 | Centelion | Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada |
| US20100111873A1 (en) | 2007-02-20 | 2010-05-06 | Russell Stephen J | Treating cancer with viral nucleic acid |
| CA2680046A1 (en) | 2007-03-23 | 2008-10-02 | The Translational Genomics Research Institute | Methods of diagnosing, classifying and treating endometrial cancer and precancer |
| WO2008133873A2 (en) | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| CL2008003449A1 (es) | 2007-11-21 | 2010-02-19 | Imclone Llc | Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer. |
| TWI526687B (zh) * | 2008-04-29 | 2016-03-21 | 諾華公司 | 生物標記 |
| EP2318529B1 (en) | 2008-08-04 | 2017-10-18 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
| US8445445B2 (en) | 2009-09-15 | 2013-05-21 | Five Prime Therapeutics, Inc. | Method of promoting hair growth using FGFR4 extracellular domains |
| LT2498799T (lt) | 2009-11-13 | 2016-11-10 | Five Prime Therapeutics, Inc. | Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis |
| WO2011084711A2 (en) | 2009-12-17 | 2011-07-14 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr3 extracellular domains |
| KR101910779B1 (ko) | 2010-11-15 | 2018-10-22 | 파이브 프라임 테라퓨틱스, 인크. | Ｆｇｆｒ１ 세포밖 도메인 조합치료 |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| IT1404531B1 (it) | 2011-02-24 | 2013-11-22 | Sisvel Technology Srl | Procedimento e sistema di localizzazione indoor per terminali mobili in una rete di telecomunicazione mobile cellulare e relativo terminale mobile. |
| AU2012229107A1 (en) | 2011-03-17 | 2013-09-19 | Novartis Ag | FGFR and ligands thereof as biomarkers for breast cancer in HR positive subjects |
| US20140294820A1 (en) | 2011-06-24 | 2014-10-02 | University Of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
| CN107823630A (zh) | 2011-11-14 | 2018-03-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
| US20160067307A1 (en) | 2013-05-01 | 2016-03-10 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
-
2012
- 2012-11-13 CN CN201711171931.8A patent/CN107823630A/zh active Pending
- 2012-11-13 US US14/357,336 patent/US10016484B2/en active Active
- 2012-11-13 CN CN201280066268.4A patent/CN104168915A/zh active Pending
- 2012-11-13 HK HK15102035.6A patent/HK1201462A1/xx unknown
- 2012-11-13 US US13/675,255 patent/US20130136740A1/en not_active Abandoned
- 2012-11-13 CA CA2855818A patent/CA2855818A1/en not_active Abandoned
- 2012-11-13 HK HK15102726.0A patent/HK1202240A1/xx unknown
- 2012-11-13 TW TW101142331A patent/TW201326201A/zh unknown
- 2012-11-13 AU AU2012318247A patent/AU2012318247B2/en active Active
- 2012-11-13 EP EP12849489.5A patent/EP2780033B1/en active Active
- 2012-11-13 JP JP2014541396A patent/JP2015505818A/ja active Pending
- 2012-11-13 WO PCT/US2012/064772 patent/WO2013074492A1/en not_active Ceased
-
2017
- 2017-05-02 JP JP2017091502A patent/JP6578318B2/ja active Active
-
2018
- 2018-06-08 US US16/003,590 patent/US10537611B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505818A5 (https=) | ||
| Chrzanowska et al. | Use of fluorescence in situ hybridization (FISH) in diagnosis and tailored therapies in solid tumors | |
| Wang et al. | Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers | |
| Durães et al. | Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? | |
| Kim et al. | The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma | |
| Smith et al. | Strategies for modern biomarker and drug development in oncology | |
| Shaib et al. | Markers of resistance to anti-EGFR therapy in colorectal cancer | |
| ES2661238T3 (es) | Biomarcadores y métodos para determinar la eficacia de anticuerpos anti-EGFR en la terapia del cáncer | |
| Cuyle et al. | Current and future biomarkers in the treatment of colorectal cancer | |
| Kim et al. | Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion | |
| Yu et al. | VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer | |
| US20140134158A1 (en) | Kras mutations and resistance to anti-egfr treatment | |
| Guo et al. | L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival | |
| Westin et al. | Personalized therapy in endometrial cancer: challenges and opportunities | |
| Capdevila et al. | Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets | |
| JP2016526016A5 (https=) | ||
| CN115176008B (zh) | 用于抑制FoxP3表达的修饰反义寡核苷酸 | |
| RU2015150233A (ru) | Способы лечения злокачественной опухоли | |
| US20140030257A1 (en) | Agtr1 as a marker for bevacizumab combination therapies | |
| Hill et al. | Targeted therapies in non-small-cell lung cancer | |
| Wang et al. | FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma | |
| Kusumaningrum et al. | A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistance | |
| Yuan et al. | CircPIK3C3 inhibits hepatocellular carcinoma progression and lenvatinib resistance by suppressing the Wnt/β-catenin pathway via the miR-452-5p/SOX15 axis | |
| Sandgren et al. | Integrative epigenomic and genomic analysis of malignant pheochromocytoma | |
| Kneissl et al. | Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines |